Nuevas perspectivas en el del paciente con infección por el virus de la inmunodeficiencia humana politratado y en fracaso virológico

Cuerda, V.J. Moreno; García, Rafael Rubio; Conejo, Montserrat Morales

doi:10.1157/13115036

Cited by 3 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to Moreno et al23 in multifailed patients, at least two active drugs can not be used, the therapeutic scheme should be kept in use until new drugs become available, assuming that there is an immunologic and clinical stability in order to avoid the use of a drug from a common chemical group which usually leads to a rapid viral resistance development, further limiting future treatment options. Geretti et al24 stated that patients in first HAART line who maintained consistently undetectable plasma viral load for a year, had a low risk of virologic failure.…”

Section: Resultsmentioning

confidence: 99%

Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasilia, Brazil during 2002–2008

Bello

Correia

Marins

et al. 2011

Drug Target�Insights

View full text Add to dashboard Cite

Little data exists concerning the efficacy of the antiretroviral therapy in the Federal District in Brazil, therefore in order to improve HIV/AIDS patients’ therapy and to pinpoint hot spots in the treatment, this research work was conducted. Of 139 HIV/AIDS patients submitted to the highly active antiretroviral therapy, 12.2% failed virologically. The significant associated factors related to unresponsiveness to the lentiviral treatment were: patients’ place of origin (OR = 3.28; IC95% = 1.0–9.73; P = 0.032) and Mycobacterium tuberculosis infection (RR = 2.90; IC95% = 1.19–7.02; P = 0.019). In the logistic regression analysis, the remaining variables in the model were: patients’ birthplace (OR = 3.28; IC95% = 1.10–9.73; P = 0.032) and tuberculosis comorbidity (OR = 3.82; IC95% = 1.19–12.22; P = 0.024). The patients enrolled in this survey had an 88.0% therapeutic success rate for the maximum period of one year of treatment, predicting that T CD4+ low values and elevated viral loads at pretreatment should be particularly considered in tuberculosis coinfection, besides the availability of new antiretroviral drugs displaying optimal activity both in viral suppression and immunological reconstitution.

show abstract

Section: Resultsmentioning

confidence: 99%

Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasilia, Brazil during 2002–2008

Bello

Correia

Marins

et al. 2011

Drug Target�Insights

View full text Add to dashboard Cite

show abstract

“…According to Moreno et al 23 in multifailed patients, at least two active drugs can not be used, the therapeutic scheme should be kept in use until new drugs become available, assuming that there is an immunologic and clinical stability in order to avoid the use of a drug from a common chemical group which usually leads to a rapid viral resistance development, further limiting future treatment options. Geretti et al 24 stated that patients in first HAART line who maintained consistently undetectable plasma viral load for a year, had a low risk of virologic failure.…”

Section: Resultsmentioning

confidence: 99%

Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasília, Brazil During 2002–2008

Bello¹,

Correia²,

Marins³

et al. 2011

dti

View full text Add to dashboard Cite

show abstract

“…Raltegravir, el primero de los inhibidores de la integrasa comercializado, ha demostrado un perfil lipídico favorable, sobre todo por el descenso de triglicé ridos en pacientes multifracasados 6,7 .…”

unclassified

Raltegravir en pacientes con infección por el virus de la inmunodeficiencia humana y alto riesgo vascular

et al. 2012

View full text Add to dashboard Cite

Nuevas perspectivas en el del paciente con infección por el virus de la inmunodeficiencia humana politratado y en fracaso virológico

Cited by 3 publications

References 15 publications

Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasilia, Brazil during 2002–2008

Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasilia, Brazil during 2002–2008

Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasília, Brazil During 2002–2008

Raltegravir en pacientes con infección por el virus de la inmunodeficiencia humana y alto riesgo vascular

Contact Info

Product

Resources

About